Article ID Journal Published Year Pages File Type
9872114 International Journal of Radiation Oncology*Biology*Physics 2005 7 Pages PDF
Abstract
Conclusion: In men with prostate cancer that has been treated with combined hormone and radiation therapy, a posttreatment PSADT of ≤8 months is associated with worse clinical outcomes and may be an early surrogate marker for decreased survival. These patients should be considered for more aggressive salvage therapy protocols.
Keywords
Related Topics
Physical Sciences and Engineering Physics and Astronomy Radiation
Preview
Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy
Authors
, , , , , ,